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Cardiac functionSympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated to determine
the focus of pharmacologic approaches targeting the sympathetic nervous system in the treatment of this
pathophysiological condition. On the other hand, therapeutic approaches aiming to protect the reduced cardiac
parasympathetic function have not receivedmuch attention. The present study evaluated rats with chronic heart
failure (six to seven weeks after coronary artery ligation) and the effects of an increased parasympathetic func-
tion by pyridostigmine (an acetylcholinesterase inhibitor) on the following aspects: arterial pressure (AP), heart
rate (HR), baroreceptor and Bezold-Jarisch reﬂex, pulse interval (PI) and AP variability, cardiac sympathetic and
parasympathetic tonus, intrinsic heart rate (i-HR) and cardiac function. Conscious rats with heart failure
exhibited no change in HR, Bezold-Jarisch reﬂex, PI variability and cardiac sympathetic tonus. On the other
hand, these animals presented hypotension and reduced baroreﬂex sensitivity, power in the low frequency
(LF) band of the systolic AP spectrum, cardiac parasympathetic tonus and i-HR,while anesthetized rats exhibited
reduced cardiac performance. Pyridostigmine prevented the attenuation of all the parameters examined, except
basal AP and cardiac performance. In conclusion, the blockade of acetylcholinesterase with pyridostigmine was
revealed to be an important pharmacological approach, which could be used to increase parasympathetic func-
tion and to improve a number of cardiocirculatory parameters in rats with heart failure.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Congestive heart failure (CHF) is characterized by increased sympa-
thetic (Liu and Zucker, 1999; Zucker, 2006; Schultz and Li, 2007; Zucker
et al., 2012) and decreased parasympathetic activity (Bibevski and
Dunlap, 1999; Dunlap et al., 2003). The imbalance of the autonomic
control is related to abnormalities in the cardiovascular reﬂexes, such
as the attenuation of the baro- and cardiopulmonary sympatho-
inhibitory reﬂexes (Wang et al., 1991). In addition, the derangement
of cardiovascular autonomic control involves an increase in the
sympatho-excitatory reﬂexes, including the cardiac sympathetic afferent
reﬂex and the chemoreﬂex (Zhu et al., 2002; Schultz and Li, 2007; Zucker
et al., 2012).
CHF produces an attenuation of the baroreﬂex in experimental
animals (Dibner-Dunlap and Thames, 1989; Chen et al., 1991;
Wang et al., 1991; Kar et al., 2011) and patients (Eckberg et al.,
1971; Kassis et al., 1986; Kassis and Amtorp, 1987). A decrease in
Bezold-Jarisch reﬂex sensitivity has been documented in rats
with myocardial infarction (Meyrelles et al., 1997; Andrade et al.,School of Medicine of Ribeirão
, SP, Brazil. Tel.: +55 16 3602
o).
r OA license.2007). However, the sensitivity of this reﬂex was found to be aug-
mented in rabbits with heart failure (Rocha et al., 2003). Therefore,
there is no consensus in the literature concerning the alteration of
the Bezold-Jarisch reﬂex among different species.
Moreover, changes in cardiac function during CHF are related to
prolonged sympathetic overactivity, which leads to cellular hypertro-
phy, apoptosis and alterations in contractile function (Singh et al.,
2001). Sympathetic overactivity has also been associated with an in-
trinsic heart rate (i-HR) decrease in patients (Jose and Taylor, 1969)
and in rats (Du et al., 2007) as well as changes in the heart rate
(HR) and arterial pressure (AP) variability in humans (La Rovere et
al., 1998) and rats (Henze et al., 2008).
Sympathetic hyperactivity and its management in CHF have been
thoroughly investigated (Liu and Zucker, 1999; Zucker, 2006; Schultz
and Li, 2007) and have led to, predominantly, the development of phar-
macologic approaches targeting the sympathetic nervous system as
part of the treatment of this pathophysiological condition (Bibevski
and Dunlap, 2011). On the other hand, therapeutic options to improve
the cardiac parasympathetic function in heart failure have not received
much attention in the literature. Nevertheless, previous studies have
demonstrated that vagal stimulation prevented the pumping incapacity
in patients with heart failure (De Ferrari et al., 2011) and reduced cardi-
ac remodeling and arrhythmias, extending the long-term survival in an-
imals models of CHF (Li et al., 2004; Zheng et al., 2005; Zhang et al.,
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therapeutic alternative to prevent the outcomes of heart failure and
improve cardiac performance.
A previous study has described that pyridostigmine bromide
(PYR) elicited a parasympathetic neurotransmission increase by
means of the inhibition of the enzymatic breakdown of acetylcholine
at cholinergic receptor sites (Androne et al., 2003). Additionally, PYR
increased HR variability in normal rats (Soares et al., 2004), healthy
humans (Nobrega et al., 2001) and patients with heart failure
(Behling et al., 2003). In healthy human beings, PYR, given for one
or two days, produced bradycardia (Dewland et al., 2007) without
modifying cardiac function (De pontes et al., 1999; Androne et al.,
2003). In patients with heart failure, PYR improved HR recovery
after exercise (Androne et al., 2003), increased the pulse interval
(PI) and reduced ventricular arrhythmia density (Behling et al.,
2003) and ameliorated the autonomic and hemodynamic proﬁle dur-
ing dynamic exercise (Serra et al., 2009). These ﬁndings demonstrate
that short-term administration of PYR has a modulatory effect on the
cardiac sympathovagal balance in healthy and heart failure subjects,
indicating that cardiovascular reﬂexes have a beneﬁcial effect. More-
over, our laboratory has observed a protective effect of PYR on cardiac
autonomic control and cardiac function 4 weeks after the onset of
heart failure in rats (unpublished data). However, the effect of PYR
on autonomic dysfunction, cardiovascular reﬂexes, HR and AP vari-
ability and heart performance has not been investigated in rats with
chronic heart failure.
Therefore, the objective of the current study was to evaluate, in
conscious rats with CHF, a more prolonged (six to seven weeks) effect
of PYR on the following issues: basal MAP and HR, baroreﬂex and
Bezold-Jarisch reﬂex, PI and systolic AP variability, cardiac auto-
nomic control and i-HR. In addition, the current study also evaluated
the cardiac function of anesthetized rats.
2. Methods
Experiments were performed on male Wistar rats (280–300 g)
that were housed individually with free access to food and water
and maintained on a 12:12 h light–dark cycle. All experimental pro-
cedures were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals [Dept. of Health, Education andWelfare,
Publication No. (NIH) 85-23, Revised 1985; Ofﬁce of Science and
Health Reports, DRR/NIH, Bethesda, MD]. The experimental protocols
used in this study were approved by the Committee of Ethics in Ani-
mal Research of the School of Medicine of Ribeirão Preto, University
of São Paulo (protocol 151/2010).
2.1. Surgical procedures
Six to seven weeks before the experiments, the animals were anes-
thetized with an intraperitoneal injection of a mixture of ketamine
(50 mg/kg, União Química Farmacêutica Nacional S/A, Embu-Guaçu,
SP, Brazil) and xylazine (10 mg/kg, Hertape Calier Saúde animal S/A,
Juatuba, MG, Brazil) and were endotracheally intubated and mechani-
cally ventilated with a respirator (Harvard Apparatus Rodent Respira-
tor, Model 680, Holliston, MA, USA). Heart failure was induced by a
coronary artery ligation as previously described by Pfeffer et al.
(1979). Brieﬂy, a left thoracotomy was performed through the ﬁfth in-
tercostal space, the pericardium was opened for heart exteriorization,
and the left anterior descending coronary artery was ligated with a
polyester suture (4–0 Ethicon, São José dos Campos, SP, Brazil). Next,
the heart was brought back to the thoracic cavity, and the incision
was sutured. The infarct size was conﬁrmed by post-mortem examina-
tion, and only rats with an infarct size >40% of the left ventricular wall
were considered. Sham-operated rats underwent a similar surgical pro-
cedure without coronary ligation. At the end of the surgery, the animals
received an analgesic (ﬂunixin meglumine, 2.5 mg/kg, sc) and werekept in the animal care of the Department Physiology of the School of
Medicine of Ribeirão Preto (University of São Paulo). For the next
three days following the surgical procedures, the animals were treated
daily with an analgesic (ﬂunixin meglumine, 2.5 mg/kg, sc). The ani-
mals were then housed for a period of six to seven weeks after the in-
duction of the myocardial infarction (or sham surgery) until the data
collection. During this period, the sham-operated rats and the rats
with heart failure received tap water or PYR (Valeant Farmacêutica do
Brasil Ltda, Campinas, SP, Brazil) dissolved in the drinking water
(0.14 mg/mL). The dose of PYR (22 mg/kg/day) used in the current
study was based on a previous study in our laboratory (unpublished
data). Two days before the experiments, the rats were anesthetized
with mixture of ketamine (50 mg/kg, União Química Farmacêutica
Nacional S/A, Embu-Guaçu, SP, Brazil) and xylazine (10 mg/kg, Hertape
Calier Saúde animal S/A, Juatuba, MG, Brazil), and polyethylene cathe-
ters were inserted into the left femoral artery and vein for the direct
measurement of AP and the administration of the drugs, respectively.
Both catheters were tunneled subcutaneously and exteriorized in the
nape of the neck, and the surgical incision sites were sutured. The ani-
mals were maintained in individual cages during the recovery until
the completion of the experimental protocol.
2.2. Experimental protocol
The animals were taken to the recording room thirty to forty mi-
nutes before the experiments, and the arterial catheter was connected
to a pressure transducer (MLT0380/D, ADInstruments, Sydney,
Australia), attached to an ampliﬁer (ML110, ADInstruments, Sydney,
Australia) and an A/D interface (Power Lab ML866, ADInstruments,
Sydney, Australia). After taking the basal recording (2 kHz) of the
AP for 30 min, the rats received, randomly, four doses (2, 4, 6 and
8 μg/kg, i.v.) of serotonin (5-HT, Sigma, St. Louis, MO, USA). Next, so-
dium nitroprusside (8 μg/kg, single bolus) and phenylephrine
(250 μg/mL, at a rate of 87 μL/min) were intravenously administered
in random order. The HR and AP were allowed to return to baseline
levels between phenylephrine and nitroprusside administration. Fi-
nally, the rats were treated with atropine (2 μg/kg, iv) and propran-
olol (4 μg/kg, iv), given 15 min apart from each other. An additional
group received the autonomic blockers in the inverse order (i.e., pro-
pranolol followed by atropine). On the next day, the rats were anes-
thetized with sodium pentobarbital (40 mg/kg ip, Rhobifarma
Indústria Farmacêutica Ltda, Hortolândia, SP, Brazil) and had a
Micro-Tip pressure catheter (SPR-407, Millar Instruments, Houston,
TX, USA) inserted into the right carotid artery and advanced into
the left ventricle (LV), as described previously (Pacher et al., 2008),
while the LV pressure was digitally (2 kHz) recorded. The LV
end-diastolic pressure (LVEDP), maximal slope of systolic pressure
increment (+dP/dtmax) and diastolic pressure decrement (−dP/
dtmax) were calculated. After the recordings, while still under anes-
thesia, the heart and lungs were rapidly removed, rinsed in ice-cold
0.9% NaCl solution and weighed. The heart was collected, and the
ventricles were cut transversally into two parts. The apex was ﬁxed
in phosphate-buffered 10% formalin and stained with picrosirius
red, to measure the infarct size. Cardiac hypertrophy was evaluated
by the cardiac weight index (heart weight/body weight ratio),
while the degree of pulmonary edema was evaluated by the lung
weight index (lung weight/body weight ratio).
2.3. Data analysis
2.3.1. PI and SAP variability
The analysis of PI and AP variability was performed from the basal
recordings using a custom-made computer software (CardioSeries-v1.1,
http://sites.google.com/site/cardioseries) developed in our laboratory.
The standard deviation of the normal intervals of PI and systolic AP
and the square root of the mean squared differences of successive PI
Table 1
[Top] Cross sections of representative hearts, stained with picosirius red, from the four
groups of rats studied. [Bottom] Group data (mean±SEM) of infarcted area (rats with
CHF) as well as body weight, heart and lung weights in sham-operated control and rats
with CHF chronically treated with PYR or water.
Sham-operated CHF
Water PYR Water PYR
Infarcted area (%) – – 55±1 57±2
Body weight (g) 529±20 519±10 515±10 510±10
Heart weight (g) 1.39±0.06 1.42±0.05 1.80±0.10⁎ 1.71±0.07⁎
Lung weight (g) 2.7±0.13 2.65±0.08 3.33±0.16⁎ 3.18±0.19⁎
MAP (mm Hg) 110±2 108±3 95±2⁎ 99±2⁎
HR (bpm) 345±10 337±10 331±9 353±7
⁎ Pb0.05 compared with sham-operated control counterparts. Bar=3 mm.
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parameters in the time domain. In addition, for the frequency domain
analysis (spectral analysis) of systolic AP and PI, a series of basal values
of these parameters were converted to data points every 100 ms using
cubic spline interpolation and were divided into half-overlapping se-
quential sets of 512 data points (51.2 s). All of the segments were visu-
ally inspected, and the nonstationary data were discarded. A Hanning
window was used to attenuate the side effects, and the spectrum of
each segment was computed using a direct Fast Fourier Transform
(FFT). The spectra were integrated in low (LF: 0.2–0.75 Hz) and high
frequency bands (HF: 0.75–3.0 Hz). To assess the sympathovagal bal-
ance, the LF/HF ratio of the HR variability was calculated (Montano et
al., 1994; Task Force of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology, 1996).
2.3.2. Bezold-Jarisch reﬂex
The Bezold-Jarisch reﬂex was evaluated by taking into account
the maximal hypotensive (Δ MAP, mm Hg) and bradycardic (Δ HR,
bpm) response elicited by the injection, at random order, of the four
doses of 5-HT.
2.3.3. Spontaneous baroreﬂex sensitivity
The baroreﬂex control of the HR was assessed through the sponta-
neous oscillations in AP and PI by the sequence method. Ramps of
progressive increases or decreases in systolic AP were automatically
identiﬁed by the computer software HemoLab-ver.14.8 (http://
www.haraldstauss.com/HemoLab/HemoLab.php) in 8000 beat series
from the basal recording period. The sequences, deﬁned by ramps of
at least four systolic AP values associated with parallel PI changes
showing linear correlation coefﬁcients higher than 0.8, were identi-
ﬁed. Spontaneous BRS was calculated as the slope (ms/mm Hg) of
the linear regression lines between the systolic AP and the subse-
quent PI intervals. The number of baroreﬂex sequences was corrected
by the number of sequences/1000 heart beats.
2.3.4. Evoked baroreﬂex sensitivity
Evoked baroreﬂex (ms/mm Hg) sensitivity was assessed as the
ratio of reﬂex PI lengthening to the phenylephrine-induced increase
in the systolic AP and as the ratio of reﬂex PI shortening to the
nitroprusside-induced fall in the systolic AP.
2.3.5. Cardiac autonomic tone and i-HR
The tachycardia obtained after atropine administration was used
as an index of cardiac vagal tonus, whereas the bradycardia elicited
by propranolol administration was used as a measure of cardiac sym-
pathetic tonus. The HR values obtained after the double autonomic
receptor blockade provided the i-HR, i.e., the HR remaining after the
removal of adrenergic and cholinergic inﬂuence on the heart.
2.3.6. Morphological analysis
The hearts were cut transversely, ﬁxed in phosphate-buffered 10%
formalin and submitted to parafﬁn embedding. Each block was serial-
ly cut with a thickness of 7 μm from the midventricular surface. The
sections were stained with picrosirius red to analyze the infarct size.
The thickness of the left ventricular wall and the infarct size were
measured using the public-domain software NIH Image J (developed
by U.S. National Institutes of Health and available at http://rsb.info.
nih.gov/nih-image/). The infarct size was calculated by dividing the
length of the infarcted area by the total circumference of the LV and
was expressed as a percentage.
2.4. Statistical analysis
The results are expressed as the mean±standard error of the
mean (SEM). The comparisons of the general characteristics of the an-
imals studied (basal MAP, HR, sympathetic tonus, vagal tonus, i-HRand cardiac function parameters) were performed using a two-way
ANOVA followed by the Tukey post-test. The differences were consid-
ered signiﬁcant for Pb0.05.
3. Results
The infarcted area was similar between the rats treated or not,
with PYR (Table 1). Table 1 shows cross sections of representative
hearts from the sham-operated and infarcted rats that received
water or PYR. The sham-operated rats showed normal ventricular
walls. On the other hand, a large scar (red color) was observed in
rats with CHF. No differences were found in the body weight among
all groups, while the heart and lung weight were greater in the rats
with CHF as compared to the sham-operated counterparts (Table 1).
3.1. Basal hemodynamics and cardiac function
The rats with CHF treated with water or PYR exhibited a lower basal
MAP, but showed a similar HR (Table 1) when compared to the
sham-operated counterparts. Moreover, the rats with CHF treated or
not with PYR exhibited lower +dP/dtmax and lower−dP/dtmax but in-
creased LVEDP as compared to the sham-operated controls (Table 2).
3.2. Bezold-Jarisch reﬂex
No differences were found in either the hypotensive (Fig. 1, upper
panel) or bradycardic responses (Fig. 1, lower panel) to the doses of
5-HT among all groups studied.
3.3. Evoked baroreﬂex sensitivity
The rats with heart failure receiving water exhibited lower sensi-
tivity for the reﬂex bradycardia (Fig. 2, left upper corner) but similar
sensitivity for the reﬂex tachycardia (Fig. 2, left lower corner) when
compared with the sham-operated counterparts. However, PYR im-
paired the attenuation of the baroreﬂex sensitivity to reﬂex bradycar-
dia in the rats with CHF.
3.4. Spontaneous baroreﬂex sensitivity
The spontaneous baroreﬂex gain, evaluated by the sequence
method, in rats with CHF was markedly reduced in animals that re-
ceived tap water. Treatment with PYR did not affect the gain of the
spontaneous baroreﬂex in the sham-operated rats. Nevertheless, in
the rats with heart failure, treatment with PYR prevented the impair-
ment of the baroreﬂex gain (Fig. 2, right upper corner). The number of
Table 2
Group data (mean±SEM) of left ventricular function parameters in sham-operated
control and rats with CHF chronically treated with PYR or water.
Sham-operated CHF
Water PYR Water PYR
+dP/dtmax
(mm Hg/s)
8303±493 8488±655 5587±379⁎ 6650±643⁎
−dP/dtmax
(mm Hg/s)
−8961±328 −9109±913 −4850±524⁎ −6007±843⁎
LV-EDP (mm Hg) 6±0.4 6±1 12±3⁎ 10±3⁎
⁎ Pb0.05 compared with sham-operated control counterparts.
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(Fig. 2, right lower corner).
3.5. PI and AP variability
Table 3 shows the group data of PI and systolic AP variability in the
rats with CHF and the sham-operated controls, treated with PYR or
water. The time domain indices of PI and systolic AP variability did
not show any differences among the groups. The spectral analysis of
PI also did not show any differences among the groups. Nevertheless,
the untreated (tap water) rats with CHF presented lower power in the
LF band of systolic AP spectra as compared to the sham-operated con-
trol rats. Treatment with PYR prevented the attenuation of LF power
of the AP spectra (Table 3).
3.6. Cardiac autonomic tone and i-HR
The rats with CHF receivingwater or PYR showed similar bradycardic
response caused by propranolol administration (cardiac sympatheticFig. 1. Dose–response curves showing the reﬂex changes in mean arterial pressure
(ΔMAP, upper panel) and heart rate (ΔHR, lower panel) in response to 2, 4, 6 and
8 μg/kg of 5-hydroxytryptamine (5-HT) in sham-operated and rats with CHF treated
with water or pyridostigmine (PYR).tonus) as compared to the sham-operated rats (Fig. 3). On the other
hand, the ratswith CHF receivingwater showed a smaller tachycardic re-
sponse caused by atropine (cardiac parasympathetic tonus), while PYR
prevented the reduction of the parasympathetic tonus in the rats with
CHF as compared to the sham-operated controls (Fig. 3). The combined
administration of atropine and propranolol showed decreased i-HR in
the rats with CHF that received tapwater, while PYR impaired this atten-
uation (Fig. 3).
4. Discussion
The results of the present study showed that PYR treatment was
able to prevent, in chronic (six to seven weeks) myocardial-induced
CHF, important cardiovascular derangements, such as the impairment
of baroreﬂex sensitivity, AP variability proﬁle, reduced cardiac vagal
tonus and changes in the i-HR. On the other hand, PYR was not effec-
tive in avoiding the reduction of AP and cardiac performance (LVEDP,
+dP/dtmax and −dP/dtmax).
After myocardial infarction, the heart usually undergoes a process
known as cardiac remodeling, which involves changes in the structure
and function of the cardiomyocytes in the noninfarcted myocardium,
leading to cardiac hypertrophy (Murdoch et al., 2006). Additionally,
the malfunction of the cardiac pump promotes the increase of pulmo-
nary capillary pressure,which, undoubtedly, determines the pulmonary
edema observed in CHF (Luz et al., 1975). In the present study, we eval-
uated, indirectly, cardiac hypertrophy and pulmonary edema by the
weight of the heart and lungs, respectively. Both the cardiac and lung
indices were augmented in the rats with CHF, and PYR treatment did
not affect any of these parameters.
As stated before, PYR failed to prevent the decrease in AP and did not
improve the cardiac function indices (LVEDP, +dP/dtmax and −dP/
dtmax). It is well to recall that the electrical stimulation of the vagus
nerve also failed to prevent hypotension in rats with CHF (Li et al.,
2004). Therefore, the electrical or pharmacological (PYR) overactivation
of the parasympathetic system failed to prevent the development of the
hypotension that occurs in rats with chronic heart failure.
The Bezold-Jarisch reﬂex is triggered, experimentally, by the intrave-
nous administration of 5-HT, which activates the cardiopulmonary re-
ceptors, particularly those conveying their action potentials through
the vagal afferent C ﬁbers producing hypotension, bradycardia and
apnea (Krayer, 1961; Kashihara, 2009). Accordingly, 5-HT administra-
tion has been considered an important tool to investigate the
Bezold-Jarisch reﬂex under normal and physiopathological conditions.
In the current study, the hypotensive and bradycardic responses to in-
creasing doses of 5-HT were unaltered in rats with CHF. However,
other studies have shown an impairment of the Bezold-Jarisch reﬂex in
infarcted rats (Meyrelles et al., 1997; Andrade et al., 2007). A possible ex-
planation for this discrepancy may be the size of the infarcted area (37%
vs. 54% in the current study), providing a different degree of heart failure.
However, the Bezold-Jarisch reﬂex sensitivity, evaluated bymeans of AP
andHR changes after administration of ATP, was augmented in infarcted
rabbits (Rocha et al., 2003). Therefore, there is no consensus in the liter-
ature concerning the alteration of the Bezold-Jarisch reﬂex in experi-
mental CHF induced by myocardial infarction.
A number of studies have demonstrated that the baroreﬂex plays an
important role in cardiocirculatory control under normal conditions
(Thrasher, 2005; Thomas, 2011). In heart diseases, such as heart failure,
a disorder of baroreﬂex function has been consistently documented
(Chen et al., 1991; Floras, 2009; Kar et al., 2011). In line with the corre-
sponding literature, the spontaneous baroreﬂex sensitivity (sequence
analysis), as well as the reﬂex bradycardia induced by the increase in
AP after phenylephrine administration, was impaired in rats with CHF.
Nevertheless, PYR treatment was able to avoid this undesirable impair-
ment in baroreﬂex sensitivity. Surprisingly, the reﬂex tachycardia to the
sodium nitroprusside-induced decrease in AP was found to be similar
among all the groups studied. Therefore, it can be hypothesized that
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Fig. 2. [Left panel] Bar graphs (mean±SEM) showing evoked reﬂex tachycardia evoked by sodium nitroprusside (top) and reﬂex bradycardia evoked by phenylephrine (bottom). [Right
panel] Bar graphs (mean±SEM) showing spontaneous baroreﬂex obtained in time domain by sequencemethod. Spontaneous baroreﬂex gain (top) and number of baroreﬂex sequences
(bottom) in sham-operated and rats with CHF. *Pb0.05 compared with sham-operated rats. #Pb0.05 compared with non-treated rats with CHF (treated with water).
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may play a strong role by impairing the parasympathetic function.
Previous studies have shown that the spectral analyses of HR and AP
variability are valuable non-invasive tools, which can be used for esti-
mating the relative autonomicmodulation of the cardiovascular system
(Pagani et al., 1986; Task Force of the European Society of Cardiology
and the North American Society of Pacing and Electrophysiology,
1996; Stauss, 2007). In addition, it has been well documented that
heart failure attenuates the HR variability, and this condition is consid-
ered to be a reliable predictor of cardiac mortality for cardiovascularTable 3
Group data (mean±SEM) of systolic arterial pressure and pulse interval variability in
sham-operated control and rats with CHF chronically treated with PYR or water.
Sham-operated CHF
Water PYR Water PYR
Systolic arterial pressure
Mean (mm Hg) 122±3 118±5 109±3 113±4
SDNN (mm Hg) 3.1±0.2 3.0±0.2 2.5±0.2 2.8±0.3
LF (mm Hg2) 3.3±0.4 3.1±1.2 1.2±0.2⁎ 2.9±0.8#
HF (mm Hg2) 1.1±0.1 1.2±0.1 1.2±0.1 1.1±0.2
Pulse interval
Mean (ms) 179±8 180±7 179±6 172±7
SDNN (ms) 3.9±0.6 4.6±0.4 4.1±0.4 5.0±0.4
RMSSD (ms) 4.6±0.6 4.0±0.4 5.0±0.6 5.6±0.5
LF (ms2) 0.8±0.2 0.7±0.2 0.6±0.1 1.7±0.4
HF (ms2) 5.1±1.3 4.4±0.7 6.8±1.7 7.7±0.9
LF (nu) 12±2 14±1 8.5±1.3 15±4
HF (nu) 88±2 86±1 91.5±1.3 85±4
LF/HF 0.15±0.03 0.18±0.02 0.10±0.02 0.24±0.08
⁎ Pb0.05 compared with sham-operated rats.
# Pb0.05 compared with non-treated rats with CHF (treated with water).diseases such as myocardial infarction or CHF (Ponikowski et al.,
1997; La Rovere et al., 1998). The time domain indices of overall PI
and AP variability were not different among the rats with chronic CHF
and the sham-operated controls. Nevertheless, the rats with CHF
showed a marked reduction of LF power of the AP spectrum, while
PYR avoided this outcome. Therefore, the current results indicate that
the pharmacological improvement of the parasympathetic function
during the development of CHF was effective in protecting against the
changes in the AP variability proﬁle.
The autonomic imbalance commonly experienced in CHF often leads
to changes in HR variability in patients (Ponikowski et al., 1997; La
Rovere et al., 1998) and experimental models of heart failure (Henze
et al., 2008). Nevertheless, in the present study, the time and frequency
domain (spectral analysis) of the PI series did not show any difference
between the sham-operated control and the rats with chronic CHF.
The downregulation of the myocardial β-adrenoceptors (Gaemperli et
al., 2010) and alterations of the cardiac sympathetic neurons, described
in animals with heart failure (Liang, 2007), might account for this dis-
crepancy. Moreover, the current results are in line with the previous
ﬁndings of Tobaldini et al. (2009), whowere also not able to detect con-
sistent autonomic alterations in rats with heart failure, due to coronary
artery ligation,when examining theHR variability. In addition, previous
clinical study using norepinephrine spillover from the heart (Kingwell
et al., 1994), as well as an experimental study using recordings of cardi-
ac sympathetic nerve activity (Jardine et al., 2002), have indicated that a
change in HR variability is not a good index of sympathetic activity.
Therefore, these evidences may explain the lack of changes in sympa-
thetic drive evaluated by means of the HR variability in the current
study.
The pharmacological blockade of the autonomic receptor showed a
decrease in cardiac vagal tonus in the rats with CHF. Dysfunction of
the parasympathetic nervous system has been documented very early
in the development of experimental heart failure (Bibevski and
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Fig. 3. [Left panel] Bar graphs (mean±SEM) showing changes in heart rate (ΔHR, bpm) after atropine (cardiac vagal tone, top) or after propranolol administration (cardiac sym-
pathetic tone, bottom) in sham-operated and rats with CHF that received water or pyridostigmine (PYR). The intrinsic heart rate (i-HR, right panel) was obtained after the double
autonomic blockade. *Pb0.05 compared with sham-operated rats. #Pb0.05 compared with non-treated rats with CHF (treated with water).
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present study, the attenuation of the parasympathetic tonus in animals
with heart failure was prevented by PYR. Therefore, these ﬁndings pro-
vide support to the notion that the blockade of the acetylcholinesterase
was effective in preserving the cardiac parasympathetic tonus after
myocardial infarction.
Surprisingly, the ratswith CHF and their sham-operated counterparts
showed a similar basal HR, while the blockade of the β-adrenoreceptors
failed to reveal a cardiac sympathetic overactivity in the rats with CHF.
The downregulation of the β-adrenoreceptor density (Gaemperli et al.,
2010) and derangement of cardiac sympathetic neurons may also be
mechanisms driving these results.
Another outcome of heart failure is the decrease of i-HR, which was
conﬁrmed in the current study. The attenuation of the i-HR has been
well documented under clinical (Jose and Taylor, 1969) and experimen-
tal situations (Du et al., 2007). Amarked decrease of sodium channel ex-
pression in the sinoatrial node cells in CHF has been demonstrated (Du
et al., 2007). Thus, the inherent downregulation of sodium channel ex-
pression contributes to heart failure-induced sinoatrial node dysfunc-
tion (Du et al., 2007) and may be responsible for the decreased i-HR.
In the current study, the i-HR was attenuated in the rats with heart fail-
ure, while PYRIDO prevented this alteration. Therefore, these ﬁndings
suggest that inhibiting acetylcholinesterase and increasing the avail-
ability of acetylcholine in the synaptic cleft was quite effective in
protecting the i-HR. However, further investigations are required to
better understand the intrinsic mechanism of PYR on the sinoatrial
node.
In conclusion, the current ﬁndings clearly showed that treatment
with PYR is an important pharmacological approach to protect the
physiological mechanisms during the development of heart failure six
to seven weeks after coronary artery ligation. This ﬁnding is supportedby the observation that PYR was remarkably efﬁcient at preventing the
attenuation of baroreﬂex sensitivity, a typical outcome of heart failure,
which was evaluated by spontaneous and evoked baroreﬂex sensitivity
assessment. In addition, PYR treatment avoided changes in i-HR and the
cardiovascular autonomic control, as examined by AP variability and
cardiac parasympathetic tonus. In contrast, the data from the current
study were not able to show a beneﬁcial effect of PYR on cardiac func-
tion in the time frame of six to seven weeks of heart failure in rats.Acknowledgments
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